Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Publication

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.

Li Li | Ling Lin | Jamunarani Veeraraghavan | Yiheng Hu | Xian Wang | Sanghoon Lee | Ying Tan | Rachel Schiff | Xiao-Song Wang
Breast cancer research : BCR | 2020

Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many genetic causes, and recent studies suggest the important role of ESR1 mutations and fusions in endocrine resistance. Previously, we reported a recurrent ESR1 fusion called ESR1-CCDC170 in 6-8% of the luminal B breast cancers that has a worse clinical outcome after endocrine therapy. Despite being the most frequent ESR1 fusion, its functional role in endocrine resistance has not been studied in vivo, and the engaged mechanism and therapeutic relevance remain uncharacterized.

Pubmed ID: 32771039

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA181368
  • Agency: NCI NIH HHS, United States
    Id: R01 CA183976
  • Agency: NCI NIH HHS, United States
    Id: P30 CA125123
  • Agency: NCI NIH HHS, United States
    Id: P30 CA008748
  • Agency: NIH HHS, United States
    Id: 1R01 CA183976
  • Agency: NCI NIH HHS, United States
    Id: P50 CA097190
  • Agency: NCI NIH HHS, United States
    Id: R21 CA237964
  • Agency: NIH HHS, United States
    Id: 1R01 CA181368

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

Cell Signaling Technology (tool)

RRID:SCR_004431

Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

View all literature mentions

ZR-75-1 (tool)

RRID:CVCL_0588

Cell line ZR-75-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

T-47D (tool)

RRID:CVCL_0553

Cell line T-47D is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HCC1428 (tool)

RRID:CVCL_1252

Cell line HCC1428 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Crl:NU(NCr)-Foxn1nu (tool)

RRID:IMSR_CRL:490

Mus musculus with name Crl:NU(NCr)-Foxn1nu from IMSR.

View all literature mentions

About

The Stimulating Peripheral Activity to Relieve Conditions (SPARC) effort is the result of National Institutes of Health’s (NIH) drive to map out the neural circuitry responsible for visceral control in higher vertebrates. The SPARC Anatomy Working Group (SAWG) is responsible for the integrity of anatomical knowledge in SPARC

Recent News Entries

Contact Us

Maryann Martone, Ph.D.

Department of Neurosciences, School of Medicine

University of California, San Diego

About SciCrunch | Privacy Policy | Terms of Service

SciCrunch